Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the Editor

Bastian Wein; Christoph Kaiser

doi:10.1016/j.ijcard.2017.10.079

Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the Editor

Int J Cardiol. 2018 Jan 15:251:33. doi: 10.1016/j.ijcard.2017.10.079.

Authors

Bastian Wein¹, Christoph Kaiser²

Affiliations

¹ Heart and Vascular Centre Oberallgaeu-Kempten, Germany. Electronic address: bastian-wein@gmx.net.
² Department of Cardiology, University Hospital of Basel, Switzerland.

PMID: 29197453
DOI: 10.1016/j.ijcard.2017.10.079

No abstract available

Keywords: Acute coronary syndrome (ACS); Clopidogrel; Cost-effectiveness; Drug eluting stent (DES); Dual antiplatelet therapy; European cohort; Prasugrel.

Publication types

Letter
Comment

MeSH terms

Acute Coronary Syndrome*
Clopidogrel
Cost-Benefit Analysis
Drug-Eluting Stents
Humans
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride*
Ticlopidine / analogs & derivatives
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine